The largest database of trusted experimental protocols

113 protocols using nicotine hydrogen tartrate salt

1

Nicotine Administration in Rodents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rats were treated SC with nicotine (nicotine-hydrogen-tartrate salt, 2 mg kg−1 every 12 h; Sigma; St Louis, MO, USA)3 (link),4 (link). Mice were house individually and implanted subcutaneously with an osmotic minipump flow moderator (Model 1002, Alzet, DURECT Corporation; Cupertino, CA, USA) containing a daily dose of 25 mg kg−1 of nicotine (nicotine-hydrogen-tartrate salt, Sigma; St Louis, MO, USA)46 (link) due to their higher metabolism, or saline. Body weight was measured for 14 days. For the central nicotine experiments, intracerebroventricular (ICV) cannulae were stereotaxically implanted under ketamine/xylazine anesthesia3 (link),33 (link),47 (link)–50 (link). Animals were individually housed and used for experimentation four days later. Then, animals were subjected to a protocol of daily ICV injections of nicotine (nicotine-hydrogen-tartrate salt, 0.3 µg day−1; Sigma; St Louis, MO, USA)51 (link) or vehicle (3 µl of saline; control mice) using a 22-gauge needle (Hamilton; Reno, NV, USA) through the inserted cannulae for 7 days.
+ Open protocol
+ Expand
2

Nicotine Withdrawal Protocol in Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
The rats in the nicotine withdrawal groups received subcutaneous injection with 6-mg/kg nicotine hydrogen tartrate salt (Sigma-Aldrich, St. Louis, MO, USA) for 17 days. And then, the injection of nicotine hydrogen tartrate salt was stopped next 2 weeks.
+ Open protocol
+ Expand
3

Pharmacological Agents for In Vivo Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
(−)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt] and dihydro-β-erythroidine hydrobromide (DHβE) were purchased from Sigma-Aldrich (St. Louis, MO). Desformylflustrabromine (dFBr) and 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl) isoxazole (CMPI) were obtained from Tocris Biosciences (Minneapolis, MN). The vehicle was a mixture of 1:1:18 [1 volume propylene glycol, 1 volume Tween-80 and 18 volumes saline]. Drug doses were chosen based on in vitro potency and available in vivo literature (Bagdas et al., 2018a (link); Moerke et al., 2016 (link); Weggel and Pandya, 2019 ). Nicotine doses are represented in the free base form. Drugs were injected intraperitoneally (i.p.) for a total volume of 1 ml/100 g body weight unless noted otherwise.
+ Open protocol
+ Expand
4

Subcutaneous and Intraperitoneal Drug Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The drugs were nicotine hydrogen tartrate salt (Sigma-Aldrich, St Louis, Missouri, USA), studied at pH 7, varenicline dihydrochloride (National Institute on Drug Abuse, Rockville, Maryland, USA), ± epibatidine dihydrochloride hydrate (Sigma-Aldrich), cytisine (Atomole Scientific, Hubei, China), cocaine hydrochloride (Sigma-Aldrich), and mecamylamine hydrochloride (Waterstone Technology LLC, Carmel, Indiana, USA). All drugs were administered subcutaneously except for cocaine and mecamylamine, which were administered intraperitoneal drugs were administered in a volume of saline equivalent to 10 ml/kg. Doses were expressed as their salt forms except for nicotine, which was expressed as the base weight.
+ Open protocol
+ Expand
5

Nicotine-Induced Conditioned Place Preference

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nicotine hydrogen tartrate salt was purchased from Sigma-Aldrich (St. Louis, MO, USA). On the first day of each experiment, the animal body weights were recorded, and nicotine solutions were prepared by dissolving 0.01 mg of nicotine per 1 mL of saline. Each administered nicotine dose was based on the individual animal body weight, and all the doses were injected via sc injections at 10 mL/kg. On the drug days of the nicotine-conditioned place preference paradigm, the mice were injected (sc) with either 0.1 or 0.5 mg/kg nicotine immediately before being placed in the nicotine-paired conditioning chamber. These doses were based on previous studies of nicotine CPP [24 (link)].
+ Open protocol
+ Expand
6

Pharmacological Evaluation of Cognitive Enhancers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Unless otherwise noted, all compounds were prepared in physiological saline (0.9% NaCl). Doses refer to the weight of the salt, except where noted. Drugs used and suppliers were: atomoxetine HCl (OChem Inc, Des Plaines, IL), donepezil HCl (Memory Pharmaceuticals, Montvale, NJ) and (−) nicotine hydrogen tartrate salt (base weight; Sigma-Aldrich, St Louis, MO). Saline served as the vehicle control in all behavioral tests.
+ Open protocol
+ Expand
7

Intravenous Nicotine Administration and Neurotransmitter Antagonists

Check if the same lab product or an alternative is used in the 5 most similar protocols
The (−)-Nicotine hydrogen tartrate salt (Sigma-Aldrich) was dissolved in sterile physiological saline (0.9% NaCl) and administered intravenously at a concentration of 30.0 μg/kg/0.1 ml infusion. The pH of the solution was adjusted to 7.4 with NaOH 5 m. The GABAA receptor antagonist bicuculline-methiodide (bicuculline) was diluted in Milli-Q to 20 mm and further diluted in artificial CSF (aCSF; 20 μm), while the AMPA receptor antagonist CNQX was dissolved in aCSF (10 μm) shortly before use. All drugs were purchased from Sigma-Aldrich.
+ Open protocol
+ Expand
8

Nicotine and Nicotinic Receptor Antagonists Pharmacology

Check if the same lab product or an alternative is used in the 5 most similar protocols
The drugs were nicotine hydrogen tartrate salt (Sigma‐Aldrich), mecamylamine hydrochloride (Waterstone Technology, LLC), and dihydro‐β‐erythroidine hydrobromide (DHβE; Tocris Bioscience). Nicotine and DHβE were administered subcutaneously, while mecamylamine was administered intraperitoneally. DHβE and mecamylamine were administered 5 min prior to operant sessions. All drugs were administered in a volume of saline equal to 10 ml/kg; nicotine solutions were adjusted to pH of 7. Drug doses are expressed as the combined weight of base and salt, except for nicotine, which is expressed as the base weight.
+ Open protocol
+ Expand
9

Nicotine Addiction Protocol for Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
(−)-Nicotine hydrogen tartrate salt (Sigma-Aldrich, St. Louis, MO) for injection was dissolved in physiological saline at a concentration of 0.1 free base mg ml−1 and pH was adjusted to 6.8–7.6. Nicotine injections were administered subcutaneously at a volume of 2 ml kg−1. Mice were sacrificed 48 hrs after nicotine injections (0.2 mg/kg), as our previous data show that the most robust, long-term addiction-related behavioral alteration occurs at this time point (19 (link)).
+ Open protocol
+ Expand
10

Masking Bitter Nicotine Flavor for Animal Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Both control and nicotine solutions contained 2% saccharin in filtered water, which was used to mask the bitter flavor of nicotine in nicotine-containing solutions (Perez et al., 2015 (link); Salas et al., 2009 (link); Zhang et al., 2012 (link)). For the majority of the experiment, nicotine bottles contained 0.1 mg/ml free-base nicotine (or 0.2804 mg/ml of nicotine hydrogen tartrate salt from Sigma Aldrich, St Louis, MO). During the “Nicotine Fading + Flavor Reintroduction” experiment, the nicotine concentration was sequentially reduced to 0.075, 0.05, 0.025, and 0.000 mg/ml (free-base). Nicotine solutions were kept in dark bottles to protect against photodegradation and were prepared fresh every 4 days. Kool-Aid ® solutions were made according to package instructions (0.14 oz powder in 2 quarts of 2% saccharin solution). Kool-Aid ® powder (Kool-Aid ® Strawberry Drink Mix Unsweetened, Kraft Foods, Chicago IL) contains flavorants, but does not contain any additional sweeteners. In other words, the only sweetener in the Kool-Aid ® solutions was the saccharin that was added during preparation of the solution.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!